ETC-1922159
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for ETC-1922159, covering 2024-10-08 to 2024-10-08. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours [Phase 1]